Key Takeaways
- • New York City venture capital deployed $2.01 billion across 75 companies in May 2026, marking a 12.0% month-over-month increase from April but representing a 16.4% year-over-year decline from May 2025's $2.40 billion.
- • Modal Labs commanded 17.7% of all NYC capital deployed with a $355 million Series B round for its AI cloud infrastructure platform, anchoring a month characterized by breadth across healthcare, insurance, fintech, and AI infrastructure rather than reliance on a single outlier deal.
- • AI-identified companies captured 66% of total funding ($1.32 billion across 32 startups), spanning clinical AI, insurance automation, investment management, and cybersecurity applications.
- • Series B activity elevated to 9 deals totaling $454.9 million (averaging $50.5 million per round), driven by large raises including RADAR's $170 million and OpenRouter's $113 million, signaling institutional confidence in revenue-stage companies.
- • Four of the top 10 deals—Vi Labs, Reserv, Garner Health, and Nourish—collectively raised $471 million, demonstrating a material reorientation of NYC late-stage capital toward health and insurance technology solutions.
Summary
New York City's venture capital market showed resilience in May 2026 with $2.01 billion deployed across 75 companies, representing a 12.0% sequential increase from April. However, the monthly strength masks underlying year-over-year weakness, with capital down 16.4% compared to May 2025's $2.40 billion total. The month was characterized by institutional appetite for mature, revenue-generating companies rather than concentration in any single transformative deal, a pattern that distinguishes May 2026 from typical venture cycles anchored by one or two outlier rounds.
Modal Labs' $355 million Series B round for AI cloud infrastructure represented the largest NYC deal of the month, accounting for 17.7% of all local capital deployed. However, the broader narrative emerged from concentrated institutional investment across healthcare and insurance technology. Four companies—Vi Labs, Reserv, Garner Health, and Nourish—collectively raised $471 million, underscoring a strategic reallocation of late-stage capital toward health and insurance tech solutions. This cohort-level deployment signals institutional confidence in solving automation and operational challenges within historically fragmented sectors.
AI-focused startups dominated capital allocation, capturing 66% of all funding with $1.32 billion distributed across 32 companies. These AI companies spanned diverse applications including clinical decision support, insurance workflow automation, investment management tools, and enterprise cybersecurity. Series B activity demonstrated particular strength, with 9 deals totaling $454.9 million and an average ticket size of $50.5 million, elevated by large rounds from RADAR ($170 million) and OpenRouter ($113 million). This elevation in Series B activity reflects institutional preference for companies demonstrating product-market fit and recurring revenue generation, a shift away from earlier-stage venture allocation typical during periods of capital constraint.
The composition of May's funding activity reveals a bifurcated market: concentrated institutional capital flowing toward mature AI infrastructure and health-tech platforms, coupled with modest velocity across 75 total companies. While deal count increased relative to May 2025, the year-over-year capital decline of 16.4% suggests that consolidation toward proven business models and established management teams continues to characterize institutional venture deployment in 2026.
Modal Labs' $355 million Series B round for AI cloud infrastructure represented the largest NYC deal of the month, accounting for 17.7% of all local capital deployed. However, the broader narrative emerged from concentrated institutional investment across healthcare and insurance technology. Four companies—Vi Labs, Reserv, Garner Health, and Nourish—collectively raised $471 million, underscoring a strategic reallocation of late-stage capital toward health and insurance tech solutions. This cohort-level deployment signals institutional confidence in solving automation and operational challenges within historically fragmented sectors.
AI-focused startups dominated capital allocation, capturing 66% of all funding with $1.32 billion distributed across 32 companies. These AI companies spanned diverse applications including clinical decision support, insurance workflow automation, investment management tools, and enterprise cybersecurity. Series B activity demonstrated particular strength, with 9 deals totaling $454.9 million and an average ticket size of $50.5 million, elevated by large rounds from RADAR ($170 million) and OpenRouter ($113 million). This elevation in Series B activity reflects institutional preference for companies demonstrating product-market fit and recurring revenue generation, a shift away from earlier-stage venture allocation typical during periods of capital constraint.
The composition of May's funding activity reveals a bifurcated market: concentrated institutional capital flowing toward mature AI infrastructure and health-tech platforms, coupled with modest velocity across 75 total companies. While deal count increased relative to May 2025, the year-over-year capital decline of 16.4% suggests that consolidation toward proven business models and established management teams continues to characterize institutional venture deployment in 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.